Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›beta 2-Microglobulin
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

beta 2-Microglobulin

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 4 min read

An 11-kDa protein associated with the outer membrane of many cells including lymphocytes.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (818 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

An 11-kDa protein associated with the outer membrane of many cells including lymphocytes. It is the small subunit of mhc class I molecules. Association with beta 2-microglobulin is generally required for the transport of class I heavy chains from the endoplasmic reticulum to the cell surface. Beta 2-microglobulin is present in small amounts in serum, cerebrospinal fluid, and urine of healthy individuals, and to a much greater degree in the urine and plasma of patients with tubular proteinuria, renal failure, or kidney transplants.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: beta 2 Microglobulin; Thymotaxin.

Where it fits in the MeSH classification

Broader topics
Histocompatibility Antigens Class I; Beta-Globulins

Related concepts

  • Lymphocytes
  • Mhc Class
  • Molecules
  • Cerebrospinal Fluid
  • Proteinuria

Research landscape

PubMed indexes 9,342 records tagged with the MeSH heading “beta 2-Microglobulin” (counts retrieved 2026-10-31). 551 of them (5.9%) were published from 2020 onward, and the busiest period so far is through 1999 with 5,388 records.

Reviews account for 658 records (7.0%) and meta-analyses for 16. Randomized controlled trials number 241 (2.6%) as a share of all records on the topic.

PubMed records by publication periodthrough 1999: 5,388 records; 2000-2009: 1,990 records; 2010-2019: 1,413 records; 2020 onward: 551 records5,388through 19991,9902000-20091,4132010-20195512020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19995,388
2000-20091,990
2010-20191,413
2020 onward551
Share of records by publication typeReviews: 7.0 percent; Meta-analyses: 0.2 percent; Randomized controlled trials: 2.6 percentReviews7.0% (658)Meta-analyses0.2% (16)Randomized controlled trials2.6% (241)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 9,342 PubMed records
TypeRecordsShare
Reviews6587.0%
Meta-analyses160.2%
Randomized controlled trials2412.6%

Method: PubMed query "beta 2-Microglobulin"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
HLA-B27 and human β2-microglobulin affect the gut microbiota of transgenic rats
Lin P, Bach M, Asquith M, Lee AY, Akileswaran L, Stauffer P, et al.
2014Research article
Design not recorded in structured metadata
195cc by
PMID 25140823 · DOI · PMC4139385
The ESAT-6 protein of Mycobacterium tuberculosis interacts with beta-2-microglobulin (β2M) affecting antigen presentation function of macrophage
Sreejit G, Ahmed A, Parveen N, Jha V, Valluri VL, Ghosh S, et al.
2014Research article
Design not recorded in structured metadata
136cc by
PMID 25356553 · DOI · PMC4214792
The structure of a β2-microglobulin fibril suggests a molecular basis for its amyloid polymorphism
Iadanza MG, Silvers R, Boardman J, Smith HI, Karamanos TK, Debelouchina GT, et al.
2018Research article
Design not recorded in structured metadata
122cc by
PMID 30375379 · DOI · PMC6207761
Adipocytes orchestrate obesity-related chronic inflammation through β2-microglobulin
Li J, Li Y, Zhou X, Yang S, Liu D, Wen H, et al.
2025Research article
Design not recorded in structured metadata
21cc by
PMID 41330906 · DOI · PMC12672573

HLA-B27 and human β2-microglobulin affect the gut microbiota of transgenic rats [1]

Research article Lin P, Bach M, Asquith M, Lee AY, Akileswaran L, Stauffer P, et al. · · 2014 · cited 195 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The HLA-B27 gene is a major risk factor for clinical diseases including ankylosing spondylitis, acute anterior uveitis, reactive arthritis, and psoriatic arthritis, but its mechanism of risk enhancement is not completely understood.
Closing excerpt
The finding that HLA-B27 is associated with altered cecal microbiota has not been shown before and can potentially provide a better understanding of the clinical diseases associated with this gene.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (208 words)

The HLA-B27 gene is a major risk factor for clinical diseases including ankylosing spondylitis, acute anterior uveitis, reactive arthritis, and psoriatic arthritis, but its mechanism of risk enhancement is not completely understood. The gut microbiome has recently been shown to influence several HLA-linked diseases. However, the role of HLA-B27 in shaping the gut microbiome has not been previously investigated. In this study, we characterize the differences in the gut microbiota mediated by the presence of the HLA-B27 gene. We identified differences in the cecal microbiota of Lewis rats transgenic for HLA-B27 and human β2-microglobulin (hβ2m), compared with wild-type Lewis rats, using biome representational in situ karyotyping (BRISK) and 16S rRNA gene sequencing. 16S sequencing revealed significant differences between transgenic animals and wild type animals by principal coordinates analysis. Further analysis of the data set revealed an increase in Prevotella spp. and a decrease in Rikenellaceae relative abundance in the transgenic animals compared to the wild type animals. By BRISK analysis, species-specific differences included an increase in Bacteroides vulgatus abundance in HLA-B27/hβ2m and hβ2m compared to wild type rats. The finding that HLA-B27 is associated with altered cecal microbiota has not been shown before and can potentially provide a better understanding of the clinical diseases associated with this gene.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 25140823 · DOI · PMC4139385

The ESAT-6 protein of Mycobacterium tuberculosis interacts with beta-2-microglobulin (β2M) affecting antigen presentation function of macrophage [2]

Research article Sreejit G, Ahmed A, Parveen N, Jha V, Valluri VL, Ghosh S, et al. · · 2014 · cited 136 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
ESAT-6, an abundantly secreted protein of Mycobacterium tuberculosis (M.
Closing excerpt
Identification of such novel interactions may help us in designing small molecule inhibitors as well as effective vaccine design against tuberculosis.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (239 words)

ESAT-6, an abundantly secreted protein of Mycobacterium tuberculosis (M. tuberculosis) is an important virulence factor, inactivation of which leads to reduced virulence of M. tuberculosis. ESAT-6 alone, or in complex with its chaperone CFP-10 (ESAT-6:CFP-10), is known to modulate host immune responses; however, the detailed mechanisms are not well understood. The structure of ESAT-6 or ESAT-6:CFP-10 complex does not suggest presence of enzymatic or DNA-binding activities. Therefore, we hypothesized that the crucial role played by ESAT-6 in the virulence of mycobacteria could be due to its interaction with some host cellular factors. Using a yeast two-hybrid screening, we identified that ESAT-6 interacts with the host protein beta-2-microglobulin (β2M), which was further confirmed by other assays, like GST pull down, co-immunoprecipitation and surface plasmon resonance. The C-terminal six amino acid residues (90-95) of ESAT-6 were found to be essential for this interaction. ESAT-6, in complex with CFP-10, also interacts with β2M. We found that ESAT-6/ESAT-6:CFP-10 can enter into the endoplasmic reticulum where it sequesters β2M to inhibit cell surface expression of MHC-I-β2M complexes, resulting in downregulation of class I-mediated antigen presentation. Interestingly, the ESAT-6:β2M complex could be detected in pleural biopsies of individuals suffering from pleural tuberculosis. Our data highlight a novel mechanism by which M. tuberculosis may undermine the host adaptive immune responses to establish a successful infection. Identification of such novel interactions may help us in designing small molecule inhibitors as well as effective vaccine design against tuberculosis.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 25356553 · DOI · PMC4214792

The structure of a β2-microglobulin fibril suggests a molecular basis for its amyloid polymorphism [3]

Research article Iadanza MG, Silvers R, Boardman J, Smith HI, Karamanos TK, Debelouchina GT, et al. · · 2018 · cited 122 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
All amyloid fibrils contain a cross-β fold.
Closing excerpt
The results provide insights into the mechanisms of fibril formation and the commonalities and differences within the amyloid fold in different protein sequences.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (148 words)

All amyloid fibrils contain a cross-β fold. How this structure differs in fibrils formed from proteins associated with different diseases remains unclear. Here, we combine cryo-EM and MAS-NMR to determine the structure of an amyloid fibril formed in vitro from β2-microglobulin (β2m), the culprit protein of dialysis-related amyloidosis. The fibril is composed of two identical protofilaments assembled from subunits that do not share β2m's native tertiary fold, but are formed from similar β-strands. The fibrils share motifs with other amyloid fibrils, but also contain unique features including π-stacking interactions perpendicular to the fibril axis and an intramolecular disulfide that stabilises the subunit fold. We also describe a structural model for a second fibril morphology and show that it is built from the same subunit fold. The results provide insights into the mechanisms of fibril formation and the commonalities and differences within the amyloid fold in different protein sequences.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 30375379 · DOI · PMC6207761

Adipocytes orchestrate obesity-related chronic inflammation through β2-microglobulin [4]

Research article Li J, Li Y, Zhou X, Yang S, Liu D, Wen H, et al. · · 2025 · cited 21 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Chronic inflammation in adipose tissue is widely recognized as a pivotal link connecting obesity to a spectrum of related chronic diseases, including type 2 diabetes, non-alcoholic fatty liver disease, and cardiovascular disorders.
Closing excerpt
Thus, our findings highlight the pivotal role of adipocytes in obesity-associated chronic inflammation and metabolic disorders via β2-microglobulin-dependent mechanisms.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (223 words)

Chronic inflammation in adipose tissue is widely recognized as a pivotal link connecting obesity to a spectrum of related chronic diseases, including type 2 diabetes, non-alcoholic fatty liver disease, and cardiovascular disorders. In this pathogenic process, the dysregulated interaction between adipocytes and adipose-resident immune cells plays a critical regulatory role; however, the underlying mechanisms governing this abnormal interaction remain largely unknown. In this study, we showed that upregulated β2-microglobulin expression in hypertrophic adipocytes during obesity not only mediated the activation of adipose-resident CD8+ T cells in a cell contact-dependent manner but also facilitated iron overload and the ferroptosis of adipocytes, thereby promoting the M1 polarization of adipose tissue macrophages. Conversely, specific ablation of β2-microglobulin in adipocytes effectively suppressed the activation and accumulation of adipose-resident CD8+ T cells, as well as adipocyte ferroptosis and M1 polarization, ultimately preventing high-fat diet-induced obesity and its related inflammation and metabolic disorders. Additionally, adeno-associated virus-mediated adipose-targeted knockdown of β2-microglobulin has been demonstrated to therapeutically alleviate high-fat diet-induced obesity, as well as its related chronic inflammation and metabolic disorders. Furthermore, our bioinformatic analysis of human adipose transcriptome data revealed a strong correlation between adipose β2-microglobulin and obesity. More importantly, β2-microglobulin is significantly upregulated in adipocytes isolated from patients with obesity. Thus, our findings highlight the pivotal role of adipocytes in obesity-associated chronic inflammation and metabolic disorders via β2-microglobulin-dependent mechanisms.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41330906 · DOI · PMC12672573

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease [5]
    Fleming RE, Sly WS · Proc Natl Acad Sci U S A · 2001 · cited 181 times (Europe PMC)
  • Research article Beta 2-microglobulin: its significance in the evaluation of renal function [6]
    Schardijn GH, Statius van Eps LW · Kidney Int · 1987 · cited 163 times (Europe PMC)
  • Research article Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy [7]
    Wang H, Liu B, Wei J · Cancer Lett · 2021 · cited 160 times (Europe PMC)
  • Research article The Implication and Significance of Beta 2 Microglobulin: A Conservative Multifunctional Regulator [8]
    Li L, Dong M, Wang XG · Chin Med J (Engl) · 2016 · cited 124 times (Europe PMC)
  • Research article Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes [9]
    Bernal M, Ruiz-Cabello F, Concha A, Paschen A, Garrido F · Cancer Immunol Immunother · 2012 · cited 96 times (Europe PMC)
  • Research article Beta-2 microglobulin in renal disease [10]
    Miyata T, Jadoul M, Kurokawa K, Van Ypersele de Strihou C · J Am Soc Nephrol · 1998 · cited 96 times (Europe PMC)

References

  1. Lin P, Bach M, Asquith M, Lee AY, Akileswaran L, Stauffer P, et al.. HLA-B27 and human β2-microglobulin affect the gut microbiota of transgenic rats. . 2014. PMID 25140823 · DOI · PMC4139385
  2. Sreejit G, Ahmed A, Parveen N, Jha V, Valluri VL, Ghosh S, et al.. The ESAT-6 protein of Mycobacterium tuberculosis interacts with beta-2-microglobulin (β2M) affecting antigen presentation function of macrophage. . 2014. PMID 25356553 · DOI · PMC4214792
  3. Iadanza MG, Silvers R, Boardman J, Smith HI, Karamanos TK, Debelouchina GT, et al.. The structure of a β2-microglobulin fibril suggests a molecular basis for its amyloid polymorphism. . 2018. PMID 30375379 · DOI · PMC6207761
  4. Li J, Li Y, Zhou X, Yang S, Liu D, Wen H, et al.. Adipocytes orchestrate obesity-related chronic inflammation through β2-microglobulin. . 2025. PMID 41330906 · DOI · PMC12672573
  5. Fleming RE, Sly WS. Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci U S A. 2001. PMID 11459944 · DOI · PMC37412
  6. Schardijn GH, Statius van Eps LW. Beta 2-microglobulin: its significance in the evaluation of renal function. Kidney Int. 1987. PMID 3323598 · DOI
  7. Wang H, Liu B, Wei J. Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy. Cancer Lett. 2021. PMID 34129878 · DOI
  8. Li L, Dong M, Wang XG. The Implication and Significance of Beta 2 Microglobulin: A Conservative Multifunctional Regulator. Chin Med J (Engl). 2016. PMID 26879019 · DOI · PMC4800846
  9. Bernal M, Ruiz-Cabello F, Concha A, Paschen A, Garrido F. Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunol Immunother. 2012. PMID 22833104 · DOI · PMC11029609
  10. Miyata T, Jadoul M, Kurokawa K, Van Ypersele de Strihou C. Beta-2 microglobulin in renal disease. J Am Soc Nephrol. 1998. PMID 9727382 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Cell Adhesion MoleculesDrugs and Chemicals
  • alpha 1-AntitrypsinDrugs and Chemicals
  • CadherinsDrugs and Chemicals
  • Carcinoembryonic AntigenDrugs and Chemicals
  • Cell Adhesion Molecule-1Drugs and Chemicals
  • E-SelectinDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

9,342
PubMed records on this heading
6%
published since 2020
658
review articles
241
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Cell Adhesion MoleculesDrugs and Chemicals
  • alpha 1-AntitrypsinDrugs and Chemicals
  • CadherinsDrugs and Chemicals
  • Carcinoembryonic AntigenDrugs and Chemicals
  • Cell Adhesion Molecule-1Drugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support